Finally, in a recent case series, two patients with non-FLT3-ITD or D835 AML were found to have JM FLT3-V592G and KD FLT3-N676K mutations, both of which clinically responded to sorafenib (146). Here, FLT3 is linked to acute myeloid leukemia.